<b>Full Title</b><br> Protocol GS-US-595-6184: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy <br><br> <b>Study Treatment</b><br> Arm A: Anti-TROP2 antibody-drug conjugate sacituzumab govitecan + pembrolizumab<br> Arm B: pembrolizumab +/- capecitabine <br><br> <b>Eligibility/Info</b><br> Non-metastatic triple negative breast cancer treated with neoadjuvant systemic therapy followed by surgery. <br><br> <b>Contact</b><br> For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: <a href="tel:631-675-5075">631-675-5075</a>. <br><br> <b>Locations</b><br> <a href="https://nycancer.com/locations/Babylon_Medical_Oncology">Babylon Medical Oncology</a><br> <a href="https://nycancer.com/locations/central_park_medical_oncology">Central Park Medical Oncology</a><br> <a href="https://nycancer.com/locations/eastchestercancercenter">Eastchester Cancer Center</a><br> <a href="https://nycancer.com/locations/lake_success_medical_oncology">Lake Success Medical Oncology</a><br> <a href="https://nycancer.com/locations/Patchogue_Medical_Oncology">Patchogue Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Medical_Oncology">Port Jefferson Medical Oncology</a><br> <a href="https://nycancer.com/locations/Port_Jefferson_Station_Medical_Oncology">Port Jefferson Station Medical Oncology</a><br> <a href="https://nycancer.com/locations/Riverhead_Medical_Oncology">Riverhead Medical Oncology</a><br>